Antibiotic for serious heart infections
Part of Heart & circulation, Infections clinical trials.
This study tests a new antibiotic called oritavancin for treating serious heart infections caused by certain bacteria. It may offer a simpler treatment option for patients who are already on antibiotics and stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Currently hospitalized for a heart infection (like endocarditis or an infection of a heart device)
- A bacteria known as Gram-positive must be found in blood or tissue samples
- No fever for at least 24 hours, and blood cultures clear for at least 24 hours
- On effective antibiotics for at least 24 hours but no more than 14 days
- No severe kidney or liver problems, no prosthetic heart valve, and not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibiotic called oritavancin for treating skin infections at the site of heart devices like pacemakers or defibrillators, especially when caused by drug-resistant bacteria. The goal is to see if this once-daily antibiotic works as well as the standard treatment.
This trial tests whether a treatment without rifampin works as well as one with rifampin for a type of heart valve infection caused by staph bacteria. It aims to find a simpler and safer option for patients with an infected artificial heart valve.
This trial measures how your body handles certain intravenous antibiotics used for endocarditis, an infection of the heart valves. It may help doctors understand the best antibiotic dosing for people with valve infections.
This study tests a better way to give a long-acting antibiotic called dalbavancin for serious bacterial infections. Dalbavancin is given as an infusion and may allow you to leave the hospital sooner while still completing your antibiotic treatment.
This study tests a new antibiotic called dalbavancin for treating infections of the heart valves. It may offer a simpler treatment option with fewer hospital visits.
This trial compares taking antibiotics by mouth versus receiving antibiotics through a vein (outpatient IV) for an infection of the heart valve. It’s designed to see whether the oral option can work as well and safely, especially after initial treatment and surgery if needed.
Hear when a new Infective Endocarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.